The association between retinal nerve fibre layer thickness and N-acetyl aspartate levels in multiple sclerosis brain normal-appearing white matter: a longitudinal study using magnetic resonance spectroscopy and optical coherence tomography

European Journal of Neurology

Volumn 23, Issue 12, 2016, Pages 1769-1774

  Pardini, M ^a   Botzkowski, D ^b   Muller S ^c   Vehoff, J ^c   Kuhle, J ^d,e   Ruberte, E ^f   Wurfel J ^f   Gass, A ^g   Valmaggia, C ^c   Tettenborn, B ^c   Putzki, N ^b   Yaldizli, O ^d  

^a UNIVERSITY OF GENOA   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e Departments of Internal Medicine and Research   (Switzerland)

^f Medical Image Analysis Center   (Switzerland)

^g UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

magnetic resonance spectroscopy; multiple sclerosis; N acetyl aspartate; optical coherence tomography; retinal nerve fibre layer thickness

Indexed keywords

BETA INTERFERON; CREATINE; GLATIRAMER; MITOXANTRONE; N ACETYLASPARTIC ACID; NATALIZUMAB; ASPARTIC ACID; N-ACETYLASPARTATE;

ADULT; AGED; ARTICLE; BRAIN; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE ASSOCIATION; DYNAMICS; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE SCORE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RETINAL NERVE FIBER LAYER THICKNESS; SCORING SYSTEM; WHITE MATTER; ANALOGS AND DERIVATIVES; AXON; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES; RETINA NERVE CELL; SENSITIVITY AND SPECIFICITY;

ADULT; ASPARTIC ACID; AXONS; BRAIN; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RETINAL NEURONS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, OPTICAL COHERENCE; WHITE MATTER;

EID: 84984819840     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.13116     Document Type: Article

References (15)

1. Mesaros S, Rocca MA, Sormani MP, Charil A, Comi G, Filippi DM. Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. J Neurol 2008; 255: 1378–1383.
2. Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain J Neurol 2002; 125(Pt 8): 1676–1695.
3. Inglese M. MRI measures of neuroprotection and repair in multiple sclerosis. J Neurol Sci 2011; 311(Suppl. 1): S16–S23.
4. Syc SB, Warner CV, Hiremath GS, et al. Reproducibility of high-resolution optical coherence tomography in multiple sclerosis. Mult Scler 2010; 16: 829–839.
5. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald criteria’. Ann Neurol 2005; 58: 840–846.
6. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907–911.
7. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993; 30: 672–679.
8. Vion-Dury J, Salvan AM, Cozzone PJ. Proton magnetic resonance spectrometry for the non-invasive exploration of human brain metabolism: current and future clinical applications. Rev Neurol (Paris) 1999; 155: 903–926.
9. Kempton MJ, Underwood TSA, Brunton S, Stylios F, Schmechtig A, Ettinger U, et al. A comprehensive testing protocol for MRI neuroanatomical segmentation techniques: evaluation of a novel lateral ventricle segmentation method. NeuroImage 2011; 58: 1051–1059.
10. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. NeuroImage 2002; 17: 479–489.
11. Kappos L, Radue E-W, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.
12. Perneger TV. What's wrong with Bonferroni adjustments. BMJ 1998; 316: 1236–1238.
13. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295–302.
14. Pfueller CF, Brandt AU, Schubert F, et al. Metabolic changes in the visual cortex are linked to retinal nerve fiber layer thinning in multiple sclerosis. PLoS One 2011; 6: e18019.
15. Bock M, Brandt AU, Dörr J, et al. Time domain and spectral domain optical coherence tomography in multiple sclerosis: a comparative cross-sectional study. Mult Scler 2010; 16: 893–896.